{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:45:33Z","timestamp":1787316333312,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T00:00:00Z","timestamp":1630972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T00:00:00Z","timestamp":1630972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tem Innovations GmbH","award":["Machines and reagents"],"award-info":[{"award-number":["Machines and reagents"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>DOAC detection is challenging in emergency situations. Here, we demonstrated recently, that modified thromboelastometric tests can reliably detect and differentiate dabigatran and rivaroxaban. However, whether all DOACs can be detected and differentiated to other coagulopathies is unclear. Therefore, we now tested the hypothesis that a decision tree-based thromboelastometry algorithm enables detection and differentiation of all direct Xa-inhibitors (DXaIs), the direct thrombin inhibitor (DTI) dabigatran, as well as vitamin K antagonists (VKA) and dilutional coagulopathy (DIL) with high accuracy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Following ethics committee approval (No 17\u2013525-4), and registration by the German clinical trials database we conducted a prospective observational trial including 50 anticoagulated patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910 of either DOAC\/VKA) and 20 healthy volunteers. Blood was drawn independent of last intake of coagulation inhibitor. Healthy volunteers served as controls and their blood was diluted to simulate a 50% dilution in vitro. Standard (extrinsic coagulation assay, fibrinogen assay, etc.) and modified thromboelastometric tests (ecarin assay and extrinsic coagulation assay with low tissue factor) were performed. Statistical analyzes included a decision tree analyzes, with depiction of accuracy, sensitivity and specificity, as well as receiver-operating-characteristics (ROC) curve analysis including optimal cut-off values (Youden-Index).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>First, standard thromboelastometric tests allow a good differentiation between DOACs and VKA, DIL and controls, however they fail to differentiate DXaIs, DTIs and VKAs reliably resulting in an overall accuracy of 78%. Second, adding modified thromboelastometric tests, 9\/10 DTI and 28\/30 DXaI patients were detected, resulting in an overall accuracy of 94%. Complex decision trees even increased overall accuracy to 98%. ROC curve analyses confirm the decision-tree-based results showing high sensitivity and specificity for detection and differentiation of DTI, DXaIs, VKA, DIL, and controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Decision tree-based machine-learning algorithms using standard and modified thromboelastometric tests allow reliable detection of DTI and DXaIs, and differentiation to VKA, DIL and controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Clinical trial number: German clinical trials database ID:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.drks.de\/drks_web\/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00015704\">DRKS00015704<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12959-021-00313-7","type":"journal-article","created":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T16:02:42Z","timestamp":1631030562000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Point-of-care detection and differentiation of anticoagulant therapy - development of thromboelastometry-guided decision-making support algorithms"],"prefix":"10.1186","volume":"19","author":[{"given":"Simon T.","family":"Sch\u00e4fer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Christine","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice-Christin","family":"Acevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"G\u00f6rlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Massberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Kammerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8357-5552","authenticated-orcid":false,"given":"Philipp","family":"Groene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,7]]},"reference":[{"issue":"26","key":"313_CR1","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","volume":"358","author":"BI Eriksson","year":"2008","unstructured":"Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al. RECORD1 study group, rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765\u201375. https:\/\/doi.org\/10.1056\/NEJMoa0800374.","journal-title":"N Engl J Med"},{"issue":"26","key":"313_CR2","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1056\/NEJMoa076016","volume":"358","author":"MR Lassen","year":"2008","unstructured":"Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, et al. RECORD3 investigators, rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776\u201386. https:\/\/doi.org\/10.1056\/NEJMoa076016.","journal-title":"N Engl J Med"},{"issue":"9591","key":"313_CR3","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","volume":"370","author":"BI Eriksson","year":"2007","unstructured":"Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370(9591):949\u201356. https:\/\/doi.org\/10.1016\/S0140-6736(07)61445-7.","journal-title":"Lancet."},{"issue":"3","key":"313_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.thromres.2010.03.021","volume":"126","author":"RJ Friedman","year":"2010","unstructured":"Friedman RJ, Dahl OE, Rosencher N, Caprini JA, Kurth AA, Francis CW, et al. RE-MOBILIZE, RE-MODEL, RE-NOVATE steering committees, dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res. 2010;126(3):175\u201382. https:\/\/doi.org\/10.1016\/j.thromres.2010.03.021.","journal-title":"Thromb Res"},{"issue":"2","key":"313_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/jth.12096","volume":"11","author":"D Garcia","year":"2013","unstructured":"Garcia D, Barrett YC, Ramacciotti E, Weitz JI. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost. 2013;11(2):245\u201352. https:\/\/doi.org\/10.1111\/jth.12096.","journal-title":"J Thromb Haemost"},{"key":"313_CR6","first-page":"462","volume":"16","author":"A Tripodi","year":"2018","unstructured":"Tripodi A, Ageno W, Ciaccio M, Legnani C, Lippi G, Manotti C, et al. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL. Blood Transfus. 2018;16:462\u201370.","journal-title":"Blood Transfus"},{"issue":"5","key":"313_CR7","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/aas.12303","volume":"58","author":"P Stein","year":"2014","unstructured":"Stein P, Bosshart M, Brand B, Schlicker A, Spahn DR, Bettex D. Dabigatran anticoagulation and Stanford type a aortic dissection: lethal coincidence: case report with literature review. Acta Anaesthesiol Scand. 2014;58(5):630\u20137. https:\/\/doi.org\/10.1111\/aas.12303.","journal-title":"Acta Anaesthesiol Scand"},{"issue":"Suppl 1","key":"313_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/ijlh.12816","volume":"40","author":"H Ten Cate","year":"2018","unstructured":"Ten Cate H, Olie RH, Ten Cate-Hoek AJ, Henskens YMC. Direct oral anticoagulants: when to consider laboratory testing? Int J Lab Hematol. 2018;40(Suppl 1):30\u20133. https:\/\/doi.org\/10.1111\/ijlh.12816.","journal-title":"Int J Lab Hematol"},{"issue":"4","key":"313_CR9","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1053\/j.jvca.2015.10.017","volume":"30","author":"GB Crapelli","year":"2016","unstructured":"Crapelli GB, Bianchi P, Isgr\u00f2 G, Biondi A, de Vincentiis C, Ranucci M. A case of fatal bleeding following emergency surgery on an ascending aorta intramural hematoma in a patient taking dabigatran. J Cardiothorac Vasc Anesth. 2016;30(4):1027\u201331. https:\/\/doi.org\/10.1053\/j.jvca.2015.10.017.","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"12","key":"313_CR10","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","volume":"375","author":"SJ Connolly","year":"2016","unstructured":"Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, et al. ANNEXA-4 investigators, Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375(12):1131\u201341. https:\/\/doi.org\/10.1056\/NEJMoa1607887.","journal-title":"N Engl J Med"},{"issue":"4","key":"313_CR11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1055\/s-0037-1599157","volume":"43","author":"GE Iapichino","year":"2017","unstructured":"Iapichino GE, Bianchi P, Ranucci M, Baryshnikova E. Point-of-care coagulation tests monitoring of direct Oral anticoagulants and their reversal therapy: state of the art. Semin Thromb Hemost. 2017;43(4):423\u201332. https:\/\/doi.org\/10.1055\/s-0037-1599157.","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"313_CR12","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1055\/s-0038-1627480","volume":"118","author":"RC Gosselin","year":"2018","unstructured":"Gosselin RC, Adcock DM, Bates SM, Douxfils J, Favaloro EJ, Gouin-Thibault I, et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct Oral anticoagulants. Thromb Haemost. 2018;118(3):437\u201350. https:\/\/doi.org\/10.1055\/s-0038-1627480.","journal-title":"Thromb Haemost"},{"key":"313_CR13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2147\/VHRM.S126265","volume":"13","author":"H Ten Cate","year":"2017","unstructured":"Ten Cate H, Henskens YM, Lanc\u00e9 MD. Practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants. Vasc Health Risk Manag. 2017;13:457\u201367. https:\/\/doi.org\/10.2147\/VHRM.S126265.","journal-title":"Vasc Health Risk Manag"},{"key":"313_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.thromres.2017.03.019","volume":"153","author":"P Fontana","year":"2017","unstructured":"Fontana P, Alberio L, Angelillo-Scherrer A, Asmis LM, Korte W, Mendez A, et al. Impact of rivaroxaban on point-of-care assays. Thromb Res. 2017;153:65\u201370. https:\/\/doi.org\/10.1016\/j.thromres.2017.03.019.","journal-title":"Thromb Res"},{"issue":"1","key":"313_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12959-017-0160-2","volume":"16","author":"YMC Henskens","year":"2018","unstructured":"Henskens YMC, Gulpen AJW, van Oerle R, Wetzels R, Verhezen P, Spronk H, et al. Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation. Thromb J. 2018;16(1):3. https:\/\/doi.org\/10.1186\/s12959-017-0160-2.","journal-title":"Thromb J"},{"key":"313_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.thromres.2017.03.018","volume":"153","author":"V Taune","year":"2017","unstructured":"Taune V, Wall\u00e9n H, \u00c5gren A, Gryfelt G, Sj\u00f6vik C, Wintler AM, et al. Whole blood coagulation assays ROTEM and T-TAS to monitor dabigatran treatment. Thromb Res. 2017;153:76\u201382. https:\/\/doi.org\/10.1016\/j.thromres.2017.03.018.","journal-title":"Thromb Res"},{"issue":"1","key":"313_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/ijlh.12744","volume":"40","author":"L Seyve","year":"2018","unstructured":"Seyve L, Richarme C, Polack B, Marlu R. Impact of four direct oral anticoagulants on rotational thromboelastometry (ROTEM). Int J Lab Hematol. 2018;40(1):84\u201393. https:\/\/doi.org\/10.1111\/ijlh.12744.","journal-title":"Int J Lab Hematol"},{"issue":"2","key":"313_CR18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s11239-019-01956-0","volume":"49","author":"MC Vedovati","year":"2020","unstructured":"Vedovati MC, Mosconi MG, Isidori F, Agnelli G, Becattini C. Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study. J Thromb Thrombolysis. 2020;49(2):251\u20138. https:\/\/doi.org\/10.1007\/s11239-019-01956-0.","journal-title":"J Thromb Thrombolysis"},{"key":"313_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.thromres.2020.04.019","volume":"190","author":"ST Sch\u00e4fer","year":"2020","unstructured":"Sch\u00e4fer ST, Wiederkehr T, Kammerer T, Acevedo A-C, Feil K, Kellert L, et al. Real-time detection and differentiation of direct oral anticoagulants (rivaroxaban and dabigatran) using modified thromboelastometric reagents. Thromb Res. 2020;190:103\u201311. https:\/\/doi.org\/10.1016\/j.thromres.2020.04.019.","journal-title":"Thromb Res"},{"issue":"2","key":"313_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/ajh.23599","volume":"89","author":"D Whiting","year":"2014","unstructured":"Whiting D, DiNardo JA. TEG and ROTEM: technology and clinical applications. Am J Hematol. 2014;89(2):228\u201332. https:\/\/doi.org\/10.1002\/ajh.23599.","journal-title":"Am J Hematol"},{"key":"313_CR21","first-page":"344","volume":"60","author":"P Groene","year":"2019","unstructured":"Groene P, Wiederkehr T, Kammerer T, Acevedo A, Brummer V, Feil K, et al. Neuartiger POC-Test detektiert die Wirkung direkter oraler Antikoagulantien (DOAK) und diskriminiert zwischen Dabigatran und Rivaroxaban in vitro und in vivo. An\u00e4sth Intensivmed. 2019;60:344\u201380.","journal-title":"An\u00e4sth Intensivmed"},{"issue":"3","key":"313_CR22","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1046\/j.1538-7836.2003.00075.x","volume":"1","author":"B S\u00f8rensen","year":"2003","unstructured":"S\u00f8rensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost. 2003;1(3):551\u20138. https:\/\/doi.org\/10.1046\/j.1538-7836.2003.00075.x.","journal-title":"J Thromb Haemost"},{"issue":"11","key":"313_CR23","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1182\/blood-2012-08-378935","volume":"121","author":"G Young","year":"2013","unstructured":"Young G, S\u00f8rensen B, Dargaud Y, Negrier C, Brummel-Ziedins K, Key NS. Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood. 2013;121(11):1944\u201350. https:\/\/doi.org\/10.1182\/blood-2012-08-378935.","journal-title":"Blood."},{"issue":"4","key":"313_CR24","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.thromres.2014.08.006","volume":"134","author":"D Adelmann","year":"2014","unstructured":"Adelmann D, Wiegele M, Wohlgemuth RK, Koch S, Frantal S, Quehenberger P, et al. Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry. Thromb Res. 2014;134(4):918\u201323. https:\/\/doi.org\/10.1016\/j.thromres.2014.08.006.","journal-title":"Thromb Res"},{"issue":"3","key":"313_CR25","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1399-6576.2007.01550.x","volume":"52","author":"C Sucker","year":"2008","unstructured":"Sucker C, Zotz RB, G\u00f6rlinger K, Hartmann M. Rotational thrombelastometry for the bedside monitoring of recombinant hirudin. Acta Anaesthesiol Scand. 2008;52(3):358\u201362. https:\/\/doi.org\/10.1111\/j.1399-6576.2007.01550.x.","journal-title":"Acta Anaesthesiol Scand"},{"issue":"5-6","key":"313_CR26","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s00508-013-0327-1","volume":"125","author":"E Schaden","year":"2013","unstructured":"Schaden E, Schober A, Hacker S, Kozek-Langenecker S. Ecarin modified rotational thrombelastometry: a point-of-care applicable alternative to monitor the direct thrombin inhibitor argatroban. Wien Klin Wochenschr. 2013;125(5-6):156\u20139. https:\/\/doi.org\/10.1007\/s00508-013-0327-1.","journal-title":"Wien Klin Wochenschr"},{"issue":"2","key":"313_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1159\/000470622","volume":"44","author":"MK K\u00f6rber","year":"2017","unstructured":"K\u00f6rber MK, Langer E, K\u00f6hr M, Wernecke K-D, Korte W, von Heymann C. In vitro and ex vivo measurement of prophylactic dabigatran concentrations with a new Ecarin-based Thromboelastometry test. Transfus Med Hemother. 2017;44(2):100\u20135. https:\/\/doi.org\/10.1159\/000470622.","journal-title":"Transfus Med Hemother"},{"issue":"5","key":"313_CR28","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/jps.24371","volume":"104","author":"M Erber","year":"2015","unstructured":"Erber M, Lee G. Production and characterization of rapidly dissolving cryopellets. J Pharm Sci. 2015;104(5):1668\u201376. https:\/\/doi.org\/10.1002\/jps.24371.","journal-title":"J Pharm Sci"},{"issue":"2","key":"313_CR29","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.ijpharm.2015.09.038","volume":"495","author":"M Erber","year":"2015","unstructured":"Erber M, Lee G. Development of cryopelletization and formulation measures to improve stability of Echis carinatus venum protein for use in diagnostic rotational thromboelastometry. Int J Pharm. 2015;495(2):692\u2013700. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.09.038.","journal-title":"Int J Pharm"},{"key":"313_CR30","volume-title":"Classification and regression trees, Taylor & Francis ltd","author":"L Breimann","year":"1984","unstructured":"Breimann L, Friedmann J, Stone C, Olshen R. Classification and regression trees, Taylor & Francis ltd. Auflage: UK ed; 1984."},{"issue":"8","key":"313_CR31","doi-asserted-by":"publisher","first-page":"362","DOI":"10.12998\/wjcc.v2.i8.362","volume":"2","author":"S Pakraftar","year":"2014","unstructured":"Pakraftar S, Atencio D, English J, Corcos A, Altschuler EM, Stahlfeld K. Dabigatran etixilate and traumatic brain injury: evolving anticoagulants require evolving care plans. World J Clin Cases. 2014;2(8):362\u20136. https:\/\/doi.org\/10.12998\/wjcc.v2.i8.362.","journal-title":"World J Clin Cases"},{"key":"313_CR32","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.clineuro.2015.05.035","volume":"136","author":"C Beynon","year":"2015","unstructured":"Beynon C, Potzy A, Sakowitz OW, Unterberg AW. Rivaroxaban and intracranial haemorrhage after mild traumatic brain injury: a dangerous combination? Clin Neurol Neurosurg. 2015;136:73\u20138. https:\/\/doi.org\/10.1016\/j.clineuro.2015.05.035.","journal-title":"Clin Neurol Neurosurg"},{"issue":"3","key":"313_CR33","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.11.019","volume":"28","author":"J Pretnar Oblak","year":"2019","unstructured":"Pretnar Oblak J, Sabovic M, Frol S. Intravenous thrombolysis after Idarucizumab application in acute stroke patients-a potentially increased sensitivity of thrombi to lysis? J Stroke Cerebrovasc Dis. 2019;28(3):768\u201373. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2018.11.019.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"1","key":"313_CR34","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1160\/TH11-12-0832","volume":"108","author":"H Mani","year":"2012","unstructured":"Mani H, Rohde G, Stratmann G, Hesse C, Herth N, Schwers S, et al. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost. 2012;108(1):191\u20138. https:\/\/doi.org\/10.1160\/TH11-12-0832.","journal-title":"Thromb Haemost"},{"key":"313_CR35","doi-asserted-by":"publisher","DOI":"10.11613\/BM.2020.010702","volume":"30","author":"S Margeti\u0107","year":"2020","unstructured":"Margeti\u0107 S, \u0106elap I, Deli\u0107 Brklja\u010di\u0107 D, Pavlovi\u0107 N, \u0160upraha Goreta S, Kobasi\u0107 I, et al. Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations. Biochem Med. 2020;30:010702.","journal-title":"Biochem Med"},{"key":"313_CR36","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009807","volume":"7","author":"M Ebner","year":"2018","unstructured":"Ebner M, Birschmann I, Peter A, H\u00e4rtig F, Spencer C, Kuhn J, et al. Limitations of specific coagulation tests for direct Oral anticoagulants: a critical analysis. J Am Heart Assoc. 2018;7:e009807.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"313_CR37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1055\/s-0038-1668098","volume":"45","author":"J Harenberg","year":"2019","unstructured":"Harenberg J, Schreiner R, Hetjens S, Weiss C. Detecting anti-IIa and anti-Xa direct Oral anticoagulant (DOAC) agents in urine using a DOAC dipstick. Semin Thromb Hemost. 2019;45(3):275\u201384. https:\/\/doi.org\/10.1055\/s-0038-1668098.","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"313_CR38","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.chest.2016.08.1462","volume":"151","author":"BT Samuelson","year":"2017","unstructured":"Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory assessment of the anticoagulant activity of direct Oral anticoagulants: a systematic review. Chest. 2017;151(1):127\u201338. https:\/\/doi.org\/10.1016\/j.chest.2016.08.1462.","journal-title":"Chest."},{"issue":"3","key":"313_CR39","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/MEJ.0b013e3283561261","volume":"20","author":"MJ Reed","year":"2013","unstructured":"Reed MJ, Nimmo AF, McGee D, Manson L, Neffendorf AE, Moir L, et al. Rotational thrombolelastometry produces potentially clinical useful results within 10 min in bleeding emergency department patients: the DEUCE study. Eur J Emerg Med. 2013;20(3):160\u20136. https:\/\/doi.org\/10.1097\/MEJ.0b013e3283561261.","journal-title":"Eur J Emerg Med"},{"issue":"2","key":"313_CR40","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1093\/bja\/aes374","volume":"110","author":"K G\u00f6rlinger","year":"2013","unstructured":"G\u00f6rlinger K, Dirkmann D, Solomon C, Hanke AA. Fast interpretation of thromboelastometry in non-cardiac surgery: reliability in patients with hypo-, normo-, and hypercoagulability. Br J Anaesth. 2013;110(2):222\u201330. https:\/\/doi.org\/10.1093\/bja\/aes374.","journal-title":"Br J Anaesth"},{"issue":"6","key":"313_CR41","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/EJA.0000000000000903","volume":"36","author":"C Pailleret","year":"2019","unstructured":"Pailleret C, Jourdi G, Siguret V, Gouin-Thibault I, Gandrille S, Stepanian A, et al. Modified ROTEM for the detection of rivaroxaban and apixaban anticoagulant activity in whole blood: a diagnostic test study. Eur J Anaesthesiol. 2019;36(6):449\u201356. https:\/\/doi.org\/10.1097\/EJA.0000000000000903.","journal-title":"Eur J Anaesthesiol"},{"issue":"2","key":"313_CR42","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/TA.0000000000002357","volume":"87","author":"JD Dias","year":"2019","unstructured":"Dias JD, Lopez-Espina CG, Ippolito J, Hsiao LH, Zaman F, Muresan AA, et al. Rapid point-of-care detection and classification of direct-acting oral anticoagulants with the TEG 6s: implications for trauma and acute care surgery. J Trauma Acute Care Surg. 2019;87(2):364\u201370. https:\/\/doi.org\/10.1097\/TA.0000000000002357.","journal-title":"J Trauma Acute Care Surg"},{"issue":"3","key":"313_CR43","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/rth2.12206","volume":"3","author":"R Artang","year":"2019","unstructured":"Artang R, Anderson M, Nielsen JD. Fully automated thromboelastograph TEG 6s to measure anticoagulant effects of direct oral anticoagulants in healthy male volunteers. Res Pract Thromb Haemost. 2019;3(3):391\u20136. https:\/\/doi.org\/10.1002\/rth2.12206.","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"313_CR44","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13054-015-0823-y","volume":"19","author":"JS Hagemo","year":"2015","unstructured":"Hagemo JS, Christiaans SC, Stanworth SJ, Brohi K, Johansson PI, Goslings JC, et al. Detection of acute traumatic coagulopathy and massive transfusion requirements by means of rotational thromboelastometry: an international prospective validation study. Crit Care. 2015;19(1):97. https:\/\/doi.org\/10.1186\/s13054-015-0823-y.","journal-title":"Crit Care"},{"issue":"6","key":"313_CR45","doi-asserted-by":"publisher","first-page":"R265","DOI":"10.1186\/cc10539","volume":"15","author":"H Sch\u00f6chl","year":"2011","unstructured":"Sch\u00f6chl H, Cotton B, Inaba K, Nienaber U, Fischer H, Voelckel W, et al. FIBTEM provides early prediction of massive transfusion in trauma. Crit Care. 2011;15(6):R265. https:\/\/doi.org\/10.1186\/cc10539.","journal-title":"Crit Care"},{"issue":"1","key":"313_CR46","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12871-017-0440-1","volume":"17","author":"C Ellenberger","year":"2017","unstructured":"Ellenberger C, Garofano N, Barcelos G, Diaper J, Pavlovic G, Licker M. Assessment of Haemostasis in patients undergoing emergent neurosurgery by rotational Elastometry and standard coagulation tests: a prospective observational study. BMC Anesthesiol. 2017;17(1):146. https:\/\/doi.org\/10.1186\/s12871-017-0440-1.","journal-title":"BMC Anesthesiol"},{"issue":"1","key":"313_CR47","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/ALN.0b013e31817885b7","volume":"109","author":"RJ Molinaro","year":"2008","unstructured":"Molinaro RJ, Szlam F, Levy JH, Fantz CR, Tanaka KA. Low plasma fibrinogen levels with the Clauss method during anticoagulation with bivalirudin. Anesthesiology. 2008;109(1):160\u20131. https:\/\/doi.org\/10.1097\/ALN.0b013e31817885b7.","journal-title":"Anesthesiology."},{"issue":"5","key":"313_CR48","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1186\/s13054-014-0538-5","volume":"18","author":"D Chappell","year":"2014","unstructured":"Chappell D, Bruegger D, Potzel J, Jacob M, Brettner F, Vogeser M, et al. Hypervolemia increases release of atrial natriuretic peptide and shedding of the endothelial glycocalyx. Crit Care. 2014;18(5):538. https:\/\/doi.org\/10.1186\/s13054-014-0538-5.","journal-title":"Crit Care"},{"key":"313_CR49","unstructured":"J. Boyd, Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guidelines, CLSI document C28-A3, Vol. 28, No. 3, 2010."}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-021-00313-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-021-00313-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-021-00313-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T03:03:52Z","timestamp":1645067032000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/s12959-021-00313-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,7]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["313"],"URL":"https:\/\/doi.org\/10.1186\/s12959-021-00313-7","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,7]]},"assertion":[{"value":"9 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original publication has been updated to include the article's coverage under Projekt DEAL.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by the Ludwig-Maximilians-University ethics committee (No 17\u2013525-4). Written informed consent was obtained from all participants before they undertook any of the study procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S.T.S. received lecture fees by CSL Behring, TEM international and Werfen as well as research grants by Octapharma and TEM International. P.G. received lecture fees by CSL Behring, A.O., T.K., A.A., S.M. declare no conflict of interest. K.G. works as medical director of TEM Innovations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}